undamentalytics Newsletter
Sign in

Humacyte, Inc. key statistics and ratios

In fiscal 2025, Humacyte, Inc. had an operating margin of -5306.0%, debt equal to 1140.0% of equity and a current ratio of 3.69. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Operating margin—<−999%<−999%
Net margin—<−999%<−999%
Free-cash-flow margin—<−999%<−999%
Return on assets−107.9%−32.1%−76.0%
Asset turnover—0.020.02
Current ratio2.403.696.21
Debt to equity—>999%116.2%
Interest cover (operating income ÷ interest)n/mn/mn/m
R&D as % of revenue—>999%>999%
Capital spending as % of revenue—43.4%17.3%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

3 of 7 checks passed · June 30, 2026
What it owns · $138m
Short-term assets $93mLonger-term assets $45m
What it owes, and who funded it · $138m
Short-term liabilities $15mLonger-term liabilities $92mShareholders' equity $31m
  • Short-term assets cover short-term liabilities $93m of assets due within a year against $15m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $93m short-term assets against $92m of longer-dated liabilities.
  • More cash than debt $80m of cash against $36m of debt.
  • Debt below 40% of shareholders' equity Debt is 116% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 25% to 116% over five years.
  • A year's operating cash flow covers at least 20% of debt −$97m of operating cash flow against $36m of debt.
  • Operating profit covers interest at least five times over Operating income of −$111m against $10m of interest.

From Humacyte, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: HUMA vs KRSACLGN vs HUMAHUMA vs KRRO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Humacyte, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Humacyte, Inc.